MARKET

TRAW

TRAW

Traws Pharma
NASDAQ
1.960
+0.240
+13.95%
After Hours: 1.960 0 0.00% 17:36 02/06 EST
OPEN
1.790
PREV CLOSE
1.720
HIGH
2.010
LOW
1.790
VOLUME
110.56K
TURNOVER
--
52 WEEK HIGH
8.61
52 WEEK LOW
0.9700
MARKET CAP
15.66M
P/E (TTM)
0.0694
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TRAW last week (0126-0130)?
Weekly Report · 5d ago
Traws Pharma initiated with a Buy at Ladenburg
TipRanks · 01/30 12:20
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 01/28 17:05
Traws Pharma Completes Phase 2 Enrollment for COVID Candidate
TipRanks · 01/26 14:01
Traws Pharma completes enrollment in Phase 2 study of ratutrelvir
TipRanks · 01/26 13:35
Traws Pharma Completes Enrollment In Ongoing 90-Patient, Open-Label Phase 2 Study Of Ratutrelvir, Investigational Oral, Ritonavir-Free Mpro/3CL Protease Inhibitor, Versus PAXLOVID, In COVID-19 Patients
Benzinga · 01/26 13:32
Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study
Reuters · 01/26 13:30
TRAWS PHARMA COMPLETES ENROLLMENT OF RATUTRELVIR CLINICAL STUDY IN PAXLOVID®-ELIGIBLE AND INELIGIBLE COVID-19 PATIENTS; ANNOUNCES PLANS FOR ADDED INDICATION FOR TIVOXAVIR MARBOXIL AS A PROPHYLACTIC TREATMENT FOR SEASONAL INFLUENZA
Reuters · 01/26 13:30
More
About TRAW
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Webull offers Traws Pharma Inc stock information, including NASDAQ: TRAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRAW stock methods without spending real money on the virtual paper trading platform.